Domov › Rakovina endometria › Rhode Island
Klinické štúdie Rakovina endometria v štáte Rhode Island
14 štúdií pre Rakovina endometria hľadá účastníkov v zariadeniach v štáte Rhode Island.
Mestá v štáte Rhode Island
Oficiálny text štúdie (anglicky)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
Prebieha náborFáza 2
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- Women and Infants Hospital, Providence
Prebieha náborFáza 1
Vek 18 a viac · Ženy · Aktualizované 2. 10. 2026 · NCT05950464Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
Prebieha náborFáza 3
Vek 18 a viac · Ženy · Aktualizované 2. 10. 2026 · NCT07198074Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Women and Infants Hospital, Providence
Prebieha náborFáza 2
Vek 18 a viac · Ženy · Aktualizované 28. 9. 2026 · NCT05112601Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Women and Infants Hospital, Providence
Prebieha náborFáza 2
Vek 18 a viac · Ženy · Aktualizované 24. 9. 2026 · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Women & Infants Hospital ( Site 5003), Providence
Prebieha náborFáza 3
Vek 18 a viac · Ženy · Aktualizované 17. 9. 2026 · NCT06952504A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Women & Infants Hospital of Rhode Island, Providence
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Providence
Prebieha náborFáza 3
Vek 18 a viac · Ženy · Aktualizované 3. 9. 2026 · NCT06989112Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Providence
Prebieha náborFáza 1/2
Vek 18 až 130 · Všetky pohlavia · Aktualizované 21. 8. 2026 · NCT05797168A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Women & Infants Hospital, Providence
Prebieha náborFáza 2
Vek 18 a viac · Ženy · Aktualizované 21. 8. 2026 · NCT05548296Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Women and Infants Hospital of Rhode Island, Providence
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 8. 2026 · NCT05579366Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Women & Infants Hospital, Providence
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 11. 2025 · NCT05997017A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Women & Infants Hospital, Providence
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 11. 2025 · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Providence
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 28. 10. 2025 · NCT03452774Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.